2014 Agenda

Tuesday, October 28, 2014
Wednesday, October 29, 2014

Tuesday, October 28, 2014

7:45 am – 5:30 pm Registration
7:45 am – 8:45 am Pipeline Café
8:45 am – 9:55 am Welcoming Remarks & Opening Plenary Session
The New Normal: Funding Models that Will Drive Innovation in the Next Decade
Public and private equity has been flowing to commercial and late stage biopharmaceutical companies, but a funding crisis persists for early-stage firms. As public investors and the reconstituted VC community favor later stage enterprises, who will fund start-ups? Is the industry going to be bifurcated into the economic have and have-nots? And, most importantly, what will the new normal be and how will it affect the pace of innovation?

Moderator:

  • Ellen B. Corenswet, Partner, Covington & Burling LLP

Panelists:

  • Laurence Blumberg, MD, Co-Founder, President & CEO, Syntimmune, Inc.
  • Robert H. Glassman, MD, Managing Director, Global Healthcare Investment Banking, Bank of America Merrill Lynch
  • Barbara S. Schilberg, Managing Director/CEO, BioAdvance
  • Peter Young, Executive-in-Residence, Pappas Ventures
10:00 am – 10:55 am Key Opinion Leader Session
Immuno-oncology Therapies: Dare We Think “Cure”?
Recent advances have markedly changed the utility of immune-oncology therapies. Therapies showing activity have included immune checkpoint inhibitors (e.g. anti-CTCL4, anti-PD1 and anti-PDL1), biospecific antibodies (e.g. CD3 and tumor antigen), CAR-T cells (e.g. CD19 chimeric TCR), GM-CSF expressing oncolytic viruses (e.g. T-Vec) and T-cell activators (e.g. agonist antibodies to OX40 or GITR) and antigen specific cancer vaccines. Synergy has been observed in combining agents with differing modes of action. In several clinical studies, long term responses have been maintained off drug, suggesting durable T-cell activation and memory, and/or complete tumor cell killing. The ability to re-repress and/or activate T-cell engagement of tumor cells represents a major advance in cancer treatment, where durable responses in the treatment of late stage patients with melanoma, NSCLC and renal carcinoma have been observed. Here we explore recent developments in this breakthrough cancer therapy field.

Moderator:

  • John Haley, PhD, Director, Developmental Therapeutics, Stony Brook University Cancer Center

Panelists:

  • Jeffrey M. Bockman, PhD, Vice President, Defined Health
  • Benjamin R. Cowen, PhD, MBA, Vice President, Business Development, PDS Biotechnology
  • Ramy Ibrahim, MD, Clinical Vice President, Immuno-Oncology, AstraZeneca
  • Jae Park, MD, Principal Investigator, Medical Oncologist, Memorial Sloan Kettering Cancer Center
10:00 am – 12:00 pm Partnering Forum
11:00 am – 11:55 am Business Workshop
Intellectual Property: Value Creation Starts Here
Intellectual property is the foundation of the value creation of every biotechnology company. How can an early-stage company or an academic innovator best protect their most important asset while still leveraging its value to the fullest? What do you need to know when in-licensing technology from an academic or research institution? What do you need to know before you negotiate with potential collaborators?

Moderator:

  • Deborah A. Somerville, Partner, Kenyon & Kenyon LLP

Panelists:

  • Peter Donnelly, Director, Technology Licensing and Industry Relations, Stony Brook University
  • Thomas Gallagher, Senior Vice President, Intellectual Property, Kadmon Corporation
  • Paul M. Richter, Jr., JD, Partner, Kenyon & Kenyon
  • Gunther Winkler, PhD, Co-Founder and Chief Executive Officer, BioMetheus
11:00 am – 12:00 pm

Summit Showcase
11:00 am: BioMarker Strategies
11:15 am: Curtana Pharmaceuticals
11:30 am: Wellesley Pharmaceuticals
11:45 am: Cyclica Inc.

Pitch Doctors:

  • Joseph V. Gulfo, MD, MBA
  • Michael Martin, PhD, Takeda Pharmaceuticals International, Inc.
  • Stephen Nagler, MEDPRO Investors LLC
  • Peter Young, Pappas Ventures
12:00 pm – 1:15 pm Lunch with the Experts
Pipeline Café
1:15 pm – 2:10 pm Key Opinion Leader Session
Precision Medicine & The Opportunity for New Therapies and Better Trials
 The “one size fits all” approach to cancer therapy is rapidly being replaced by precision medicine. Landmark advances in tumor genomics have resulted in new cancer drugs that target specific molecular alterations or cell signaling pathways, yielding unprecedented anti-cancer activity. The National Cancer Institute’s recently launched “exceptional responders” initiative is examining failed clinical trials for patients who responded well to drugs that the bulk of the trial population did not, with the goal of identifying so-called failed drugs that may have value in very specific patient populations. Join our panelists as they explore the rapidly changing scientific, clinical and commercial landscape as precision medicine becomes the new normal.

Moderator:

  • Querida Anderson, Editor in Chief, BioPharm Insight

Panelists:

  • Mohan Chellani, MBA, PhD, President, Progen LifeSciences
  • Bruce R. Conway, PhD, Program Director, Robertson Therapeutic Development Fund, The Rockefeller University
  • Cecilia Schott, PharmD, Head Personalized Healthcare, Corporate Development & Ventures, AstraZeneca
  • David B. Solit, MD, Geoffrey Beene Chair, Director, Center for Molecular Oncology, Memorial Sloan-Kettering Cancer Center
1:15 pm – 2:15 pm

Summit Showcase
1:15 pm: Biometheus, LLC
1:30 pm: RGenix
1:45 pm: Cynvec LLC
2:00 pm: Intezyne, Inc.

Pitch Doctors:

  • Laurence Blumberg, MD, Syntimmune, Inc.
  • Jarrod Borkat, MedImmune
  • Klaudyne Hong, PhD, Temasek Bioscience Partners
  • William S. Podd, Landmark Angels, Inc.
  • Amir P. Tamiz, PhD, NIH/NINDS
1:15 pm – 4:30 pm Partnering Forum
2:15 pm – 3:10 pm Business Workshop
Collaboration: How to Court Strategic Partners
Strategic partnerships between emerging biotech companies and established biopharmaceutical companies are an important source of financial support as well as validation for early-stage companies. Often there is a mismatch between the expectations of emerging companies and what the interests are of the larger potential partner. What do fledgling entrepreneurs need to understand about larger strategic partners to approach them successfully?

Moderator:

  • James Foley, PhD, Managing Director, Aqua Partners, LL

Panelists:

  • Peter I. Bernstein, Partner, Scully, Scott, Murphy & Presser, P.C.
  • Jarrod Borkat, Head, External Collaborations and Biotech Hubs, MedImmune
  • Pamela R. Demain, Executive Director, Transactions, Business Development & Licensing, Merck ­­­
2:15 pm – 3:15 pm

Summit Showcase
2:15 pm: AiCure
2:30 pm: Intensity Therapeutics
2:45 pm: DiamiR Biosciences
3:00 pm: Cloud Pharmaceuticals, Inc.

Pitch Doctors:

  • Janelle Anderson, MRL Ventures Fund
  • Mostafa Analoui, PhD, Livingston Securities
  • Dennis J. Purcell, Aisling Capital LLC
  • Cecilia Schott, PharmD, AstraZeneca
3:15 pm – 3:30 pm Coffee Break – Sponsored by
EisnerAmper
3:30 pm – 4:25 pm Business Workshop
Understanding How to Work with a Banker: Raising Your First Professional Round
What do entrepreneurs and innovators need to know before seeking investment outside their friends and family? You need to have a good story about your science and the market potential for your asset, but you should also know some of the basics about deal structure before sitting down with a professional financial advisor for the first time. This panel will discuss the key role bankers can play in leading an early-stage company through the process of seeking investment, as well as deal structure basics.

Moderator:

  • John Pennent, Partner, EisenerAmper

Panelists:

  • William D. “Chip” Baird, Chief Financial Officer, Amicus Therapeutics
  • Sherry Grisewood, CFA, Managing Director, Corporate Finance, Dawson James Securities, Inc.
3:30 pm – 4:30 pm

Summit Showcase

3:30 pm: Merck
3:45: MedImmune
4:00: AstraZeneca
4:15: Abbvie

4:30 pm – 5:30 pm Plenary Session
From Whence the ‘Next Big Thing’
Pharmaceutical R&D has been suffering from a lack of innovation for years, and more and more big pharma is resolved to look for the next big thing in start-up biotechs or in academic labs. Most major pharmaceutical companies have established partnerships with academic research institutions. How are these collaborations faring? Should we expect more creative approaches to sourcing innovation? What are venture investors doing to support this critical ecosystem?

Moderator:

  • Joseph V. Gulfo, MD, MBA, Author, Biopharma/Medtech CEO, Professor

Panelists:

  • Karen Akinsanya, Associate Vice President, early-stage Assessment & Alliance Management Lead, Merck
  • Dennis J. Purcell, Senior Managing Director, Aisling Capital LLC
  • Cecilia Schott, PharmD, Head Personalized Healthcare, Corporate Development & Ventures, AstraZeneca
  • Jeremy Springhorn, PhD, Vice President, Corporate Strategy and Business Development, Alexion Pharmaceuticals, Inc.
5:30 pm – 7:00 pm Pipeline Café
Partnering Reception

 

Wednesday, October 29, 2014

8:00 am – 3:00 pm Registration
8:15 am – 9:00 am Pipeline Café
9:00 am – 9:55 am Plenary Session
Investors Speak: What Do Investors Want in an Early-Stage Company?
Venture investment in biotech is poised to reach new highs by the end of 2014, but early-stage companies still face an uphill battle to get funded. What are investors looking for in preclinical/phase I companies? Our panel of seasoned early-stage investors will share their investment criteria and offer insight into how young drug companies can gain investor support.

Moderator:

  • Kimberly Ha, Senior Director, FTI Consulting

Panelists:

  • Les Funtleyder, Director of Strategic Investments, OPKO Health, Healthcare Portfolio Manager, E Squared Asset Management
  • Alexander S. Preker, President & Chief Executive Officer, Health Investment & Financing Corporation
  • Barbara S. Schilberg, Managing Director/Chief Executive Officer, BioAdvance Ventures
  • Anthony Y. Sun, MD, Partner, Aisling Capital
  • Terry C. Vance, Chief Business Officer, BioMotiv
10:00 am – 10:55 am Key Opinion Leader Session
The Human Microbiome: Human Health and (Dys)Function
The human body is home to trillions of microorganisms that are believed to contribute to nutrition, developmental regulation of intestinal angiogenesis, protection from pathogens, and development of the immune response. It is believed that pathogens, antibiotic use, diet, inflammation, and other forces can alter the microbiome and lead to disease. Advances in genome sequencing technologies and metagenomic analysis are providing a broader understanding of these resident microbes and highlighting differences between healthy and disease states. Join our panel of human microbiome experts as they share their approach to augment and harness the human microbiome for the development of new therapies, and explore the challenges and opportunities associated with this emerging field.

Moderator:

  • Christopher Morrey, PhD, Editor , BMC-series Journals, BioMed Central

Panelists:

  • Mary S. Consalvi, Partner, Proskauer Rose LLP
  • Peter DiLaura, President & Chief Executive Officer, Second Genome, Inc.
  • John C. March, PhD, Associate Professor, Cornell University; Chief Scientific Advisor, Biopancreate
  • Gregory Verdine, PhD, Founder & Chief Executive Officer, Warp Drive Bio, LLC
  • Geoffrey von Maltzahn, PhD, New Ventures Principal, Flagship Ventures
10:00 am – 12:00 pm Partnering Forum
11:00 am – 11:55 am Business Workshop
Communications Strategy: Why it Matters for An Early-Stage Company
Communications strategy is often far down the list of priorities for most emerging biotech entrepreneurs, but neglecting to develop and refine your company’s story can be an expensive mistake in the long run. In an environment with a shrinking pool of investors, a company needs to deliver its value proposition in a clear, concise and consistent message that is accessible to multiple audiences – scientific, financial, strategic partners and media.

Moderator:

  • Sherry Grisewood, CFA, Managing Director, Corporate Finance, Dawson James Securities, Inc.

Panelists:

  • Jane Baj, Director, Corporate Communications, PTC Therapeutics, Inc.
  • Jim DeMesa, Chief Executive Officer, Integene International
  • Jason Rando, Executive Vice President & Chief Operating Officer, Tiberend Strategic Advisors
  • Felicia Vonella, Director, Investor Relations & Corporate Communications, Acorda Therapeutics
11:00 am – 12:00 pm

Summit Showcase
11:00 am: Cell Source
11:15 am: Indi Molecular
11:30 am: Agene Bio, Inc.
11:45 am: Neurotez

Pitch Doctors:

  • Les Funtleyder, OPKO Health; E Squared Asset Management
  • Michael Martin, PhD. Takeda Pharmaceuticals International, Inc.
  • Alexander S. Preker, Health Investment & Financing Corporation
  • Amir P. Tamiz, PhD, NIH/NINDS
  • Terry C. Vance, BioMotiv
12:00 pm – 1:10 pm Lunch with the Experts
Pipeline Café
1:15 pm – 2:10 pm Key Opinion Leader Session
Fresh Perspectives and New Opportunities in Alzheimer’s Disease Therapeutic Development
More than 5 million Americans suffer from Alzheimer’s disease today, and without new drugs to prevent or halt progression that number is expected to increase to 15 million by 2050. Cost of care will increase from $200 billion to a staggering $1.2 trillion a year. Our panelists will touch upon the challenges of developing new therapeutic options for AD, and explore emerging approaches that hold promise in the fight against Alzheimer’s disease. From novel in-silico design and computational approaches to disease progression, to new applications of FDA approved drugs and traditional drug development approaches, the session will explore the latest, and most promising advances in the field of AD research.

Moderator:

  • Howard Fillit, MD, Founding Executive Director and Chief Science Officer, Alzheimer’s Drug Discovery Foundation

Panelists:

  • Michela Gallagher, PhD, Krieger Eisenhower Professor, Psychology & Neuroscience, Johns Hopkins School of Medicine; Founder and Chief Scientific Officer, Agenebio
  • Magali Haas, MD, PhD, Founder and Chief Executive Officer, Orion Bionetworks
  • Ashish Raj, PhD, Associate Professor of Neuroscience, Brain Mind Research Institute, Weill Cornell Medical College
  • Rachel Schindler, MD, Vice President, Clinical Disease Area Expert, Neurosciences & Alzheimer’s disease, Pfizer, Inc.
1:15 pm – 2:15 pm

Summit Showcase
1:15 pm: Amorsa Therapeutics, Inc.
1:30 pm: Zocere, Inc.
1:45 pm: Nanometics
2:00 pm: Integene

Pitch Doctors:

  • George De Sanctis, Sanofi
  • Klaudyne Hong, PhD, Temasek Bioscience Partners
  • Kristen C. Kosofsky, Horizon Technology Finance
  • Peter Young, Executive-in-Residence, Pappas Ventures
1:15 pm – 4:30 pm Partnering Forum
2:15 pm – 3:10 pm Business Workshop
Family Offices: How to Attract Patient Capital
The Panel will discuss the emergence of Family Offices as a viable alternative for funding life science and device companies, why Family Offices are looking to invest in healthcare companies, where has this capital been previously, how active are Family Offices in this sector and how is Social Impact Investing affecting Family Office choices.

Moderator:

  • William S. Podd, President & Executive Director, Landmark Angels, Inc.

Panelists:

  • Harry Edelson, CFA. General Partner, Edelson Technology Partners
  • Dan Farrell, Chairman & CEO, Privos Capital
  • David Nage, President, AccessGroup Holdings, LLC
  • Jennifer P. Seibert, M.Sc. MBA, Chief Executive Officer, GAP Ventues
  • Peter Young, Entrepreneur-in-Residence, Pappas Ventures
2:15 pm – 3:15 pm

Summit Showcase
2:15 pm: Formula Pharmaceuticals, Inc.
2:30 pm: Provista Diagnostics, Inc.
2:45 pm: ioGenetics, Inc.
3:00 pm: Induce Biologics

Pitch Doctors:

  • Franklin M. Berger, CFA, FMB
  • Sanjeev Munshi, Merck
  • Stephen Nagler, MEDPRO Investors LLC
  • Barbara S. Schilberg, Managing Director/Chief Executive Officer, BioAdvance
3:15 pm – 3:30 pm Coffee Break
3:30 pm – 4:30 pm Business Workshop
Non-Dilutive Funding: An Important Tool For Every Emerging Company
With traditional venture capitalists turning their attention to later stage, de-risked investment opportunities, non-dilutive funding sources are more important than ever to emerging companies. Federal government grants, debt financing and medical foundations are some of the sources of non-dilutive capital that are available to early-stage companies.

Moderator:

  • Jonathan Cohen, President & Chief Executive Officer, 20/20 Genesystems Inc.

Panelists:

  • B. Stuart Jacobowitz, Director of Business Development, Freemind Group LLC
  • Kristen C. Kosofsky, Managing Director, Horizon Technology Finance
  • Amir P. Tamiz, PhD, Progr am Manager, Office of Translational Research, NIH/NINDS
4:30 pm – 5:30 pm Closing Plenary Session & Reception
IPOs, Generalists, Angels: Is the Biotech Rally Sustainable?
The current biotech rally is going into its second year. Will this boom market go the way of previous market windows, or are the fundamentals different this time? The industry as a whole has matured since the genomic bubble of 2000. Can it attract and sustain the generalist investors that are required to maintain a viable public market? And as public capital and most VC investment focuses on commercial, or Phase III companies, how will early-stage companies be funded?

Moderator:

  • Barbara Ryan, Managing Director, Strategic Communications Practice, FTI Consulting

Panelists:

  • Edwin H. Gordon, Head of Healthcare and Life Sciences Group, Ladenburg Thalman
  • Misti Ushio, PhD, Managing Director and Executive Vice President, Harris & Harris Group, Inc.
  • Gregory Verdine, PhD, Founder & Chief Executive Officer, Warp Drive Bio, LLC